Catalyst Pharma receives two new US patent allowances for FIRDAPSE, extending IP protection to mid-2032

CATALYST PHARMACEUTICALS, INC.

USPTO allowed two patents covering FIRDAPSE bioavailability under fasting/fed conditions; expected grant within two months.
Patents expire mid-2032; will be listed in FDA Orange Book, raising total listed patents to eight.
CEO states patent exclusivity in US until 2037; these new patents strengthen IP estate.
FIRDAPSE is only approved US treatment for Lambert-Eaton myasthenic syndrome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.